12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Relovair fluticasone furoate/vilanterol: Phase III data

Top-line data from a 12-week, placebo-controlled, Phase III trial evaluating lung function in approximately 600 mild to moderate asthmatics showed 100/25 µg Relovair fluticasone furoate/vilanterol did not significantly improve trough FEV1 (p=0.405) or weighted mean FEV1 (p=0.06) vs. 100...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >